Why Pfizer Stock Is Bouncing Back
For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But today, analysts at Citigroup put out a note suggesting that Pfizer is lowballing the market and setting itself up to beat earnings in 2024.
Pfizer stock is up 3.1% through 10:50 a.m. ET in response.
On Wednesday last week, Pfizer guided investors on what to expect from it in 2024. With demand for COVID-19-related vaccines and treatment continuing to dwindle, Pfizer predicted sales of Comirnaty (the Pfizer coronavirus vaccine) and Paxlovid (the Pfizer treatment for coronavirus) will total only about $8 billion next year. The company's acquisition of Seagen will add about $3.1 billion worth of oncology sales. But even so, total sales for the year will range from only $58.5 billion to $61.5 billion -- so $60 billion at the midpoint, which works out to about 4% year-over-year growth.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 27.62 € bedeuten.